AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BeiGene's Stock Surges 72.23% in Trading Volume Ranking 446th Amidst Biotech Boom
Generated by AI AgentAinvest Volume Radar
Thursday, Jul 17, 2025 6:03 pm ET1min read
Aime SummaryOn July 17, 2025, BeiGene's trading volume reached HK$234 million, marking a 72.23% increase from the previous day. The company's stock ranked 446th in terms of trading volume for the day. BeiGene's shares have been on a steady rise, increasing by 4.01% and marking the fourth consecutive day of gains, with a total increase of 16.00% over the past four days.
BeiGene's Hong Kong-listed shares experienced a significant surge following the acceptance of its DLL3/CD3 bispecific antibody, tarlatamab, for review. This development has sparked investor interest and contributed to the company's recent stock performance.
Biotechnology stocks, including
, showed strong performance. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. rose by 23.90%, KEYMED BIO-B increased by 12.40%, and AKESO gained 10.16%. Innovative drug concept stocks also performed well, with Lepu Biopharma leading the way with a rise of over 13%. KEYMED BIO-B increased by over 12%, AKESO rose by more than 10%, and INNOVENT BIO, WUXI BIO, and Hengrui Pharmaceuticals all saw gains.
Ainvest Volume Radar
Hunt down the stocks with explosive trading volume.
Latest Articles
Kraft Heinz Slides 1.02% as Stock Ranks 486th in Daily Trading Volume Amid Institutional Splits Earnings Woes and Dividend Strain Weigh on Investor Confidence
Dec.05 2025
AVAV's 3.15% Slide Amid 21% Volume Drop, 475th Rank Signal Earnings Optimism Fizzles
Dec.05 2025
Align Technology Extends Three-Day Rally with 0.24 Gain Ranks 452nd in $250M Turnover as Dental Sector Outperforms Peers
Dec.05 2025
PPG's 0.36% Rise Outpaces 448th-Ranked Volume as Analysts Boost Aerospace Growth Outlook
Dec.05 2025
Akamai's FedRAMP Certification Drives 31.33% Volume Surge to 445th Rank, but Stock Dips 3.59% on Investor Caution
Dec.05 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet